These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21321287)

  • 1. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
    Katz MH
    Arch Intern Med; 2011 Jun; 171(11):1004-5. PubMed ID: 21321289
    [No Abstract]   [Full Text] [Related]  

  • 3. Inverse association between duration of use of acid-suppressive medications and fracture risk.
    de Vries F
    Arch Intern Med; 2011 Jun; 171(11):1044; author reply 1044. PubMed ID: 21670381
    [No Abstract]   [Full Text] [Related]  

  • 4. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure in patients treated with bisphosphonates.
    Grove EL; Abrahamsen B; Vestergaard P
    J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
    McGowan B; Bennett K; Barry M
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
    Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
    J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
    Chiu HF; Huang YW; Chang CC; Yang CY
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors and bone fractures?
    Laine L
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S21-6. PubMed ID: 19262543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal and gastric cancer incidence and mortality in alendronate users.
    Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
    J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
    Kaye JA; Jick H
    Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
    Abrahamsen B; Vestergaard P
    Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
    J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.